Xu Jianping, Liu Xiaoyan, Yang Sheng, Shi Yuankai
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.
J Cancer Res Ther. 2022 Sep;18(5):1425-1431. doi: 10.4103/jcrt.jcrt_1853_21.
Anti-angiogenesis drugs are applicable in treating advanced non-small cell lung cancer (NSCLC); however, the related data regarding apatinib, a Chinese domestic anti-vascular endothelial growth factor receptor-2 (VEGFR-2) production, are limited. Therefore, this study explored the efficacy and safety of apatinib plus platinum doublet chemotherapy in treating patients with advanced NSCLC.
Twenty-four patients with advanced NSCLC were retrospectively enrolled. All patients received platinum doublet chemotherapy combined with apatinib 250 mg daily. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events were analyzed.
Zero (0.0%), seven (29.2%), 11 (45.8%), and six (25.0%) patients had partial response (PR), stable disease (SD), and progressed disease (PD), respectively, resulting in an ORR of 29.2% and a DCR of 75.0%. The median PFS was 12.6 months (95% CI: 3.9-21.3 months) with a 1-year PFS of 56.1%, and the median OS was 18.3 months (95% CI: 13.0-23.5 months) with a 1-year OS of 73.9%. Age ≤60 years (P = 0.034), ECOG performance score 1 (vs. 2; P = 0.005), and first-line treatment (vs. second or higher line treatment; P = 0.043) correlated with longer PFS. The most common treatment-related adverse events included fatigue (83.3%), nausea (79.2%), myelosuppression (70.8), and vomiting (66.7%), while most of them were mild and manageable. Only four (16.6%) patients witnessed grade 3-4 myelosuppression.
Apatinib plus platinum doublet chemotherapy is effective and well-tolerated in treating patients with advanced NSCLC; moreover, reduced ECOG PS and lower lines of treatment relate to its better efficacy.
抗血管生成药物可用于治疗晚期非小细胞肺癌（NSCLC）；然而，关于国产抗血管内皮生长因子受体-2（VEGFR-2）药物阿帕替尼的相关数据有限。因此，本研究探讨了阿帕替尼联合铂类双药化疗治疗晚期NSCLC患者的疗效和安全性。
回顾性纳入24例晚期NSCLC患者。所有患者接受铂类双药化疗联合阿帕替尼每日250mg治疗。分析客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）及不良事件。
分别有0例（0.0%）、7例（29.2%）、11例（45.8%）和6例（25.0%）患者出现部分缓解（PR）、疾病稳定（SD）和疾病进展（PD），ORR为29.2%，DCR为75.0%。中位PFS为12.6个月（95%CI：3.9 - 21.3个月），1年PFS率为56.1%；中位OS为18.3个月（95%CI：13.0 - 23.5个月），1年OS率为73.9%。年龄≤60岁（P = 0.034）、东部肿瘤协作组（ECOG）体能状态评分为1（对比2；P = 0.005）以及一线治疗（对比二线或更高线治疗；P = 0.043）与更长的PFS相关。最常见的治疗相关不良事件包括疲劳（83.3%）、恶心（79.2%）、骨髓抑制（70.8%）和呕吐（66.7%），而大多数为轻度且可控制。仅4例（16.6%）患者出现3 - 4级骨髓抑制。
阿帕替尼联合铂类双药化疗治疗晚期NSCLC患者有效且耐受性良好；此外，较低的ECOG体能状态评分和较低的治疗线数与其更好的疗效相关。
